Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Currency
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
Halozyme (RV7) Ownership - Who Owns Halozyme?
0 Followers
Halozyme (RV7) Ownership Overview
The ownership structure of Halozyme (DE:RV7) stock is a mix of institutional, retail and individual investors. Approximately 24.21% of the company’s stock is owned by Institutional Investors, 0.00% is owned by Insiders and 75.79% is owned by Public Companies and Individual Investors.
0.00% Insiders
0.00% Mutual Funds
24.21% Other Institutional Investors
75.79% Public Companies and
Individual Investors
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Aug 15, 2023 | James M. Daly Director | Sold | $874500 |
| Mar 01, 2023 | Jeffrey William Henderson Director | Sold | $962200 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Sep 30, 2023 | Sold | $269768 | |
| Sep 30, 2023 | Sold | $343800 | |
| Sep 30, 2023 | Sold | $1203300 | |
| Sep 30, 2023 | Bought | $1608449 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 187,004.00 | Insider | ― | 6,919,148.00 | |
| 364,320.00 | Insider | ― | 13,479,840.00 | |
| 623,666.00 | Insider | ― | 23,075,642.00 | |
| 338,051.00 | Insider | ― | 12,507,887.00 | |
| 113,254.00 | Insider | ― | 4,190,398.00 | |
| 179,833.00 | Insider | ― | 6,653,821.00 | |
| 14,092,771.00 | Insider | ― | 521,432,527.00 | |
| 13,638.00 | Insider | ― | 504,606.00 | |
| 66,815.00 | Insider | ― | 2,472,155.00 | |
| 66,373.00 | Insider | ― | 2,455,801.00 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 502,710.00 | Institution | ― | 18,600,270.00 | |
| 4,426.00 | Institution | ― | 163,762.00 | |
| 295,322.00 | Institution | ― | 10,926,914.00 | |
| 178,303.00 | Institution | ― | 6,597,211.00 | |
| 12,345.00 | Institution | ― | 456,765.00 | |
| 500,000.00 | Institution | ― | 18,500,000.00 | |
| 60,285.00 | Institution | ― | 2,230,545.00 | |
| 387,505.00 | Institution | ― | 14,337,685.00 | |
| 868,111.00 | Institution | ― | 32,120,107.00 | |
| 26,833.00 | Institution | ― | 992,821.00 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Halozyme Therapeutics (DE:RV7)?
According to the latest TipRanks data, approximately 24.21% of the company's stock is held by institutional investors, 0.00% is held by insiders, and 75.79% is held by retail investors.
What percentage of Halozyme Therapeutics (DE:RV7) stock is held by institutional investors?
According to the latest TipRanks data, approximately 24.21% of Halozyme Therapeutics (DE:RV7) stock is held by institutional investors.
What percentage of Halozyme Therapeutics (DE:RV7) stock is held by retail investors?
According to the latest TipRanks data, approximately 75.79% of Halozyme Therapeutics (DE:RV7) stock is held by retail investors.
Who owns the most shares of Halozyme Therapeutics (DE:RV7)?
Connie Matsui owns the most shares of Halozyme Therapeutics (DE:RV7).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.